Clinical Testing News and Research

RSS

Animal models of Huntington's disease allow better insights into disease's genetics

Scientific progress in Huntington's disease (HD) relies upon the availability of appropriate animal models that enable insights into the disease's genetics and/or pathophysiology.

23 Apr 2013

Preclinical data on anti-cancer activity of BI-505 published online in Cancer Cell

BioInvent International AB, a biotech company developing novel antibody therapeutics for treatment of cancer, today announced that the April 15, 2013 online issue of the highly prestigious cancer research journal Cancer Cell features a data publication demonstrating potent anti-cancer activity of BI-505 in multiple preclinical myeloma tumor models.

17 Apr 2013

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.

11 Apr 2013

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its Targeted Antibody Payload technology, disclosed for the first time today preclinical data for its EGFR-targeting ADC, IMGN289.

11 Apr 2013

Immunotherapy and epigenetics advancements presented by Ludwig at the American Association for Cancer Research

A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at this week’s American Association for Cancer Research (AACR) Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment implications for emerging cancer therapy.

10 Apr 2013

New chemotherapy regimen appears to produce minimal side effects in lung cancer patients

A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps shrink tumors, according findings to be presented by Fox Chase Cancer Center researchers at the AACR Annual Meeting 2013 on Tuesday, April 9.

10 Apr 2013

TSRI scientists receive innovative grant to help people break nicotine addiction

As part of an unprecedented national effort to develop new drugs to treat neurological disorders, scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded an innovative grant from the National Institute of Neurological Disorders and Stroke to help people break their addiction to nicotine.

28 Mar 2013

TSRI scientists awarded innovative grant to develop anti-smoking drug candidates

As part of an unprecedented national effort to develop new drugs to treat neurological disorders, scientists from the Florida campus of The Scripps Research Institute have been awarded an innovative grant from the National Institute of Neurological Disorders and Stroke to help people break their addiction to nicotine.

28 Mar 2013

Non-invasive prenatal genetic screening: an interview with Dr. Charles Strom, Senior Medical Director, Quest Diagnostics

A new category of non-invasive genetic screening tests is gaining a great deal of interest in the medical field – including from Quest Diagnostics -- for its potential to help screen women during pregnancy for genetic abnormalities known as trisomies, the most common of which is Down syndrome.

From Quest Diagnostics 13 Mar 2013

Endocrine Society issues position statement on estradiol measurement

In a Position Statement unveiled today, The Endocrine Society advocates that all methods for measuring estrogens, which play a crucial role in human biology, be made traceable to a common standard.

6 Mar 2013

CellAegis Devices to use autoRIC Device for Chronic Remote Ischemic Conditioning

CellAegis Devices, Inc., announced today that it has received an Investigational Testing Approval from Health Canada that allows the initiation of clinical testing in Canada of the Company's autoRIC Device for Chronic Remote Ischemic Conditioning (CRIC).

27 Feb 2013

Glide Pharma announces completion of $21.4 million investment round

Glide Pharma, the pharmaceutical development and device company focused on the needle-free administration of solid dose formulations, today announced that it has completed a £14.0 million ($21.4 million) investment round.

26 Feb 2013

Thermo Fisher Scientific launches Brilliance GBS Agar

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of Brilliance GBS Agar for the testing of Group B streptococci (GBS) during pregnancy.

From Thermo Fisher Scientific Inc. 26 Feb 2013

Familial Hypercholesterolaemia patients often inherit small-effect changes in several genes rather than a large-effect mutation in a single gene

Research published Online First in The Lancet provides new evidence that a substantial proportion of individuals with a clinical diagnosis of Familial Hypercholesterolaemia (FH) inherit a combination of small-effect changes in several genes (polygenic) rather than a large-effect mutation in a single gene (monogenic).

22 Feb 2013

Breast cancer tests: an interview with Dr Steven Quay, CEO of Atossa Genetics

Breast cancer is a major concern throughout the world. It is the number 1 cancer among women and in the Western world it generates approximately one new case per minute: 24 hours a day 7 days a week.

22 Feb 2013

North Carolina researchers successfully coat polymer implants with YSZ bioactive film

Researchers from North Carolina State University have for the first time successfully coated polymer implants with a bioactive film. The discovery should improve the success rate of such implants - which are often used in spinal surgeries.

20 Feb 2013

FDA allows Scioderm’s SD-101 IND application for Epidermolysis Bullosa to proceed

Scioderm announced that the US Food and Drug Administration (FDA) has reviewed and allowed the investigational new drug (IND) application for SD-101 to proceed. SD-101 is a topical treatment being developed for the treatment of Epidermolysis Bullosa (EB).

14 Feb 2013

Underwriters Laboratories announces new non-clinical lab, resources and capabilities for biocompatibility in North America

UL (Underwriters Laboratories), a world leader in advancing safety, announced today the expansion of the South Bend, Indiana analytical laboratory to offer non-clinical testing services for the medical device industry.

13 Feb 2013

GSK, Vanderbilt partner to develop and commercialize new therapies for severe obesity

Vanderbilt University announced today that it has signed a collaboration agreement with GlaxoSmithKline (GSK) for the discovery, development and commercialization of novel therapies for severe obesity.